Clinical

Dataset Information

0

A Study of AbGn-107 in Patients With Gastric, Colorectal, Pancreatic or Biliary Cancer


ABSTRACT: This study is to define the safety profile and to determine the Maximal tolerated dose regimen and preliminary efficacy of AbGn-107 administered every 14 days (Q2W regimen) or 28 days (Q4W regimen) in patients with chemo-refractory locally advanced, recurrent or metastatic gastric, colorectal, pancreatic or biliary cancer.

DISEASE(S): Adenocarcinoma,Biliary Cancer,Biliary Tract Neoplasms,Gastric Cancer,Colorectal Cancer,Pancreatic Cancer,Cancer

PROVIDER: 2225595 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2015-03-01 | E-GEOD-59856 | biostudies-arrayexpress
2012-03-01 | E-GEOD-34166 | biostudies-arrayexpress
2015-03-01 | GSE59856 | GEO
2024-01-01 | GSE249385 | GEO
| PRJNA80809 | ENA
2022-03-03 | GSE155498 | GEO
2021-10-25 | GSE186444 | GEO
2012-03-01 | GSE34166 | GEO
2023-11-21 | E-MTAB-13501 | biostudies-arrayexpress
2020-09-09 | GSE157661 | GEO